Echo Biopharmaceutical Group Zhejiang Qiqi Pharmaceutical

Echo Biopharmaceutical Group, often associated with its subsidiary Zhejiang Qiqi Pharmaceutical, is a clinical-stage biotechnology company focused on the development of innovative therapies for metabolic diseases. The company specializes in the discovery and optimization of peptide-based drugs, particularly multi-receptor agonists targeting GLP-1, GIP, and glucagon receptors. Their lead programs aim to address significant unmet needs in type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging their proprietary peptide engineering platform, Echo Biopharmaceutical Group aims to create next-generation metabolic treatments with improved efficacy and safety profiles. The company maintains a strong research and manufacturing presence in China, positioning itself as a key player in the rapidly evolving metabolic health sector.